Andrew Partheniou is Vice President, Research at Stifel GMP covering the health care, cannabis and psychedelics sectors, where he joined its predecessor firm GMP Securities L.P. (“GMP”) in 2017. He provided support to Martin Landry who has been ranked as a TopGun Analyst in the Small Cap/Special Situations and Healthcare sectors in the Brendan Wood International Worldwide Equity Capital Markets Performance — Canadian Equities Report. Mr. Partheniou has a technical background stemming from his years at a global engineering conglomerate and holds both a B. Eng. from McGill University, and an MBA from the John Molson School of Business.
Cannabis More Like a Staple Than a Discretionary Product
October 13, 2022